Pre-emptive Liver Protection
William Aryitey |
One in 50 patients who take an interferon-β (IFN-β) biologic to treat multiple sclerosis have adverse side effects that cause liver injury; up to 60 percent present with abnormal biochemical liver tests. Although the treatment benefits many, the detriment to these patients cannot be overlooked – so a group of researchers hope to help with new biomarkers for liver injury caused by IFN-β (1). These biomarkers may make it possible to predict whether a patient is susceptible to liver injury.
Just a Breath Away
A new diagnostic for pancreatic cancer may come from an unlikely source: your breath! A study of volatile organic compounds in breath has found that they act as novel biomarkers to detect the disease (2). GC/MS analysis of exhaled air can allow diagnosticians to identify patients with pancreatic cancer with 81 percent sensitivity.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.